High Throughput Mass Spec-Based Screening Assay Trends 2014
|出版日||ページ情報||英文 52 Pages
|ハイスループット質量分析によるスクリーニングアッセイ High Throughput Mass Spec-Based Screening Assay Trends 2014|
|出版日: 2014年11月18日||ページ情報: 英文 52 Pages||
This market report summarizes the results of HTStec's industry-wide global web-based benchmarking survey on high throughput (HT) mass spectrometry (MS)-based screening assays carried out in November 2014.
The survey was initiated by HTStec as part of its tracking of emerging life science marketplaces and to update our previous report in MS-based screening assays (published February 2013).
The questionnaire was compiled to meet the needs, requirements and interests of the MS analysis and screening assays vendor community. The objectives were to comprehensively document the current approaches to implementation and use of HT MS-based screening assays, and to understand future user requirements/preferences.
Equal emphasis was given to soliciting opinion from Pharma, Biotech and Academic Research market segments in both North America and Europe.
The survey looked at the following aspects of MS-based screening assays, as practiced today (2014) and in a few cases as predicted for the future (2016): areas where MS-based screening assays are currently used; what is most analysed by MS-based assays; key diseases/therapeutic area(s) targeted with MS-based assays; target classes most interested in applying MS-based screening assay approaches; types of biological samples most analysed using MS-based screening assay approaches; ADME applications of greatest interest; most compelling drivers for wanting to use MS-based screening assays; biggest limitations associated with MS-based screening assays; potential issues associated with MS-based screening assays limiting work today; label-free technologies/approaches displaced by MS-based screening assays; what constitutes truly high throughput screening (HTS) in respondent's labs; is the sample throughput achievable with the Agilent RapidFire RF365 adequate for primary screening (HTS) needs; compatibility requirements of an MS platform with low volume sample utilization (<5µl) and 1536-well plates; use of compound pools and multiplexing strategies to facilitate deployment of MS-based primary screening; FTE devoted in house to MS-based screening assay research and number of different targets/projects/programs supported; MS-based screening assay development time; MS-based primary screening (HTS) assay metrics; estimated cost per sample (well) analysed using MS-based screening assays; MS-based screening systems implemented to achieve moderate to high throughput and walkway sample automation; how many MS detection units are there available in respondent's screening/profiling facilities; approach to MS system automation most likely to adopt in future; budgets and plans to purchase MS-based screening systems; most wanted types of MS detection; most appealing vendors of MS detection system and sample automation; areas where high throughput MS-based screening assays or approaches are expected to make the biggest future impact; approach to enabling truly high throughput automated MS-based screening assays expected to gain most traction in the drug screening community in the future; extent to which potential hurdles of surface-based MS platforms represent major limitations; level of agreement with statements about the status of HT MS-based screening assays; and any unmet needs in MS-based screening assays today.
The main questionnaire consisted of 28 multi-choice questions and 2 open-ended questions. In addition, there were 6 questions related solely to the administration of the survey.
The survey collected 64 validated responses, of these 75% provided comprehensive input.
Responses were geographically split: 45% North America; 28% Europe; 14% Asia (excluding Japan & China); 9% Japan and 3% China.
Survey respondents were drawn from persons or groups undertaking MS-based screening assays or planning future investigation in this area.
Respondents represented 19 University/Research Institute/Government Lab/Not-For-Profit; 12 Large Pharma; 8 Contract Research Organisation; 7 Medium-Small Pharma; 6 Biotech Company; 5 Biopharma; 3 Medical School/ Hospital/Clinic; 3 Other; and 1 Forensics.
Most survey respondents had a senior job role or position which was in descending order: 14 research scientists; 8 lab managers; 8 principal investigators; 7 section/group leaders; 6 senior scientists/researchers; 5 directors; 4 department heads; 3 other roles; 2 graduate/PhD students; 2 post-docs; 2 professors/assistant professors; 2 automation engineers; and 1 vice president.
Respondents had the followings main group activities: 17% basic research; 14% primary screening (HTS); 13% bioanalysis; 12% a combination of drug discovery areas; 9% assay development; 9% other activities; 8% therapeutic areas (target ID/validation); 5% hits-to-leads (lead optimization); 5% applied research; 3% secondary screening; 3% leads-to-candidate (ADME tox/preclinical research); and 2% compound profiling.
Survey results were expressed as an average of all survey respondents. In addition, where appropriate the data was reanalyzed after sub-division into the following 5 survey groups: 1) Pharma; 2) Biotech; 3) Academic Research; 4) North America; and 5) Europe.
69% of respondents were currently using MS-based approaches for biological screening or label-free assays, the remainder aspire to or intend to implement or outsource in the near future.
Most respondents plan or make use of MS-based assays mainly for primary screening (HTS).
Substrates/metabolites/reaction products were ranked the material most want to analyze using MS-based screening assays.
The majority of respondents were targeting MS-based screening assays within the oncology area.
Kinases were the target class most were interested to analyse by MS-based screening approaches.
Soluble aliquots taken from homogeneous assays were the biological samples most were interested to analyse by MS-based screening approaches.
Metabolic stability was rated the ADME area most were interested in applying MS-based screening.
Ability to quantify multiple analytes simultaneously in a single sample was rated the most compelling reason for using MS-based screening assays.
Feedback on the biggest limitations (obstacles) of using MS-based screening today was documented, most concerns were about the instrumentation costs and lack of high throughput.
High cost of instrumentation was ranked the main limitation associated with MS-based screening.
Protein-ligand NMR was rated the alternative label-free technology/approach that MS-based screening is most likely to displace.
A median of 1K-5K samples processed per 24 hour day constitutes true HTS in respondent's labs.
The majority of respondents thought the throughput achievable with Agilent Rapidfire RF365 (1hour/384 plate) was adequate for their HTS needs.
Regarding the future deployment of MS-technology platforms for primary screening compatibility with 1536 plates and lower volume sample utilization (<5µL) were both rated 'nice to have' options.
Most respondents were interested in compound pooling and multiplexing to facilitate deployment of HT MS-based primary screening assays. The median pool size wanted was 10 or less test compounds/well and the multiplexing strategy of greatest interest was using different targets in the same assay.
A median of 1-5 full-time equivalent (FTE) were devoted in house to MS-based screening assays.
A median of 1-5 different MS-based targets/projects/programs were supported/lab/year.
A median assay development time of 1-2 weeks was reported for MS-based assays.
A median of 2 MS-based primary screens were performed/year with a median of <1k wells/screen today. A median price of $2-$5/sample (well) analysed was paid using MS-based assays approaches.
Most respondents have not yet implemented specific MS-based automated solutions in house to achieve HT screening and walkaway automation.
A median of 3 MS-based detection units were available in respondents screening facilities.
Most respondents have plans to purchase a new MS-based screening system over the coming years. The approach most attractive to respondents was a complete (turnkey) solution including integrated MS, automated ONline sample storage/feed, sample prep, injection and data analysis.
The median budget allocation for a new MS system was $250K-$500K, with 1 unit per budget and the most cited reason for purchase was to get extra screening capacity.
The market of high throughput MS-based screening systems was estimated to be around $90M in 2014.
The type of MS detection system respondents were most interested in deploying (either alone or with an LC) for HT biological screening and analysis was an MS-MS.
The most preferred vendors of MS detection systems were AB Sciex, Agilent, and Thermo Scientific.
The most preferred vendors of MS sample automation were Agilent, Thermo Scientific and Tecan.
HT MS-based screening assays are expected to impact primary screening (HTS) most in the future.
The approach to HT automated MS-based assays expected to gain most traction in drug screening over the coming years will be injection-based MS that typically involves ONline sample prep.
Respondents level of agreement with some statements about the status of MS-based screening assays was most positive (i.e. greatest agreement) with 'enabling truly HT MS-based HTS will have far-reaching implications'; and most negative (i.e. greatest disagreement) with 'MS-based assays will never be the preferred screening format for all assays'.
Some feedback on any unmet needs in MS-based screening approaches today were documented.
The full report provides the data, details of the breakdown of the responses to each question, its segmentation and estimates for the future (2016). It also highlights some interesting differences, particularly between the survey groups.